Estrogen receptor phosphorylation by MAPK . R S THOMAS and others 183 Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA & Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 753–758. Bunone G, Briand PA, Miksicek RJ & Picard D 1996 Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO Journal 15 2174–2183. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S & Nakshatri H 2001 Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor a: a new model for anti-estrogen resistance. Journal of Biological Chemistry 276 9817–9824. Chen D, Riedl T, Washbrook E, Pace PE, Coombes RC, Egly JM & Ali S 2000 Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and partici- pation of CDK7. Molecular Cell 6 127–137. Chen D, Washbrook E, Sarwar N, Bates GJ, Pace PE, Thirunuvakkarasu V, Taylor J, Epstein RJ, Fuller-Pace FV, Egly JM et al. 2002 Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-speciﬁc antisera. Oncogene 21 4921–4931. Couse JF & Korach KS 1999 Estrogen receptor mice: what have we learned and where will they lead us? Endocrine Reviews 20 358–417. Curtis SW, Washburn T, Sewall C, DiAugustine R, Lindzey J, Couse JF & Korach KS 1996 Physiological coupling of growth factor and steroid receptor signaling pathways: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. PNAS 93 12626–12630. Gee JM, Robertson JF, Ellis IO & Nicholson RI 2001 Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. International Journal of Cancer 95 247–254. Glass CK & Rosenfeld MG 2000 The coregulator exchange in transcriptional functions of nuclear receptors. Genes and Development 14 121–141. Le Goff P, Montano MM, Schodin DJ & Katzenellenbogen BS 1994 Phosphorylation of the human estrogen receptor. Identiﬁcation of hormone-regulated sites and examination of their inﬂuence on transcriptional activity. Journal of Biological Chemistry 269 4458–4466. Gronemeyer H 1991 Transcription activation by estrogen and progesterone receptors. Annual Review of Genetics 25 89–123. Henderson IC & Piccart-Gebhart MJ 2005 The evolving role of aromatase inhibitors in adjuvant breast cancer therapy. Clinical Breast Cancer 6 206–215. Ignar-Trowbridge DM, Nelson KG, Bidwell MC, Curtis SW, Washburn TF, McLachlan JA & Korach KS 1992 Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. PNAS 89 4658–4662. Ignar-Trowbridge DM, Teng CT, Ross KA, Parker MG, Korach KS & McLachlan JA 1993 Peptide growth factors elicit estrogen receptor- dependent transcriptional activation of an estrogen-responsive element. Molecular Endocinology 7 992–998. Ignar-Trowbridge DM, Pimentel M, Parker MG, McLachlan JA & Korach KS 1996 Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology 137 1735–1744. Joel PB, Traish AM & Lannigan DA 1995 Estradiol and phorbol ester cause phosphorylation of serine 118 in the human estrogen receptor. Molecular Endocinology 9 1041–1052. Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J & Lannigan DA 1998a pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Molecular Cell Biology 18 1978–1984. Joel PB, Traish AM & Lannigan DA 1998b Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. Journal of Biological Chemistry 273 13317–13323. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H et al. 1995 Activation of the estrogen receptor through phosphorylation by mitogen- activated protein kinase. Science 270 1491–1494. www.endocrinology-journals.org Kurokawa H & Arteaga CL 2003 ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clinical Cancer Research 9 511S–515S. Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT & Arteaga CL 2000 Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Research 60 5887–5894. Lipfert L, Fisher JE, Wei N, Scafonas A, Su Q, Yudkovitz J, Chen F, Warrier S, Birzin ET, Kim S et al. 2006 Antagonist-induced, AF-2 independent estrogen receptor a phosphorylation. Molecular Endocinology 20 516–533. McDonnell DP, Clemm DL, Hermann T, Goldman ME & Pike JW 1995 Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Molecular Endocinology 9 659–669. Medunjanin S, Hermani A, De Servi B, Grisouard J, Rincke G & Mayer D 2005 Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor a and is involved in the regulation of receptor activity. Journal of Biological Chemistry 280 33006–33014. Metzger D, Losson R, Bornert JM, Lemoine Y & Chambon P 1992 Promoter speciﬁcity of the two transcriptional activation functions of the human oestrogen receptor in yeast. Nucleic Acid Research 20 2813–2817. Nettles KW & Greene GL 2005 Ligand control of coregulator recruitment to nuclear receptors. Annual Review of Physiology 67 309–333. Obenauer JC, Cantley LC & Yaffe MB 2003 Scansite 2.0: proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acid Research 31 3635–3641. Osborne CK 1998 Tamoxifen in the treatment of breast cancer. New England Journal of Medicine 339 1609–1618. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX & Slamon DJ 1995 HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10 2435–2446. Rogatsky I, Trowbridge JM & Garabedian MJ 1999 Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. Journal of Biological Chemistry 274 22296–22302. Ross JS & Fletcher JA 1998 The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16 413–428. Sarwar N, Kim JS, Jiang J, Peston D, Sinnett HD, Madden P, Gee JM, Nicholson RI, Lykkesfeldt AE, Shousha S et al. 2006 Phosphory- lation of ERa at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERa phosphorylation in breast cancer progression. Endocrine- Related Cancer 13 851–861. Shang Y & Brown M 2002 Molecular determinants for the tissue speciﬁcity of SERMs. Science 295 2465–2468. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA & Greene GL 1998 The structural basis of estrogen receptor/coacti- vator recognition and the antagonism of this interaction by tamoxifen. Cell 95 927–937. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H & Schiff R 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. Journal of National Cancer Institute 96 926–935. Smith CL 1998 Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biology of Reproduction 58 627–632. Smith CL, Nawaz Z & O’Malley BW 1997 Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Molecular Endocinology 11 657–666. Journal of Molecular Endocrinology (2008) 40, 173–184